Maia Wealth LLC Buys New Position in Pfizer Inc. (NYSE:PFE)

Maia Wealth LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,794 shares of the biopharmaceutical company’s stock, valued at approximately $372,000.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Olistico Wealth LLC acquired a new position in Pfizer in the 2nd quarter valued at $25,000. Creekmur Asset Management LLC acquired a new position in Pfizer in the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the period. Tennessee Valley Asset Management Partners acquired a new stake in Pfizer in the 4th quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new stake in Pfizer in the 4th quarter valued at about $37,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.3 %

Pfizer stock traded down $0.10 during midday trading on Wednesday, hitting $28.75. 1,335,980 shares of the company were exchanged, compared to its average volume of 39,426,891. The company has a market cap of $162.91 billion, a PE ratio of -480.75, a price-to-earnings-growth ratio of 1.02 and a beta of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.19. The company’s fifty day moving average price is $28.77 and its 200-day moving average price is $27.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.67 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.84%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.